研究单位：[1]Eli Lilly and Company ( Loxo Oncology,Inc. )[2]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650032[3]Mayo Clinic Hospital Phoenix,Arizona,United States,85054[4]City of Hope National Medical Center Duarte,California,United States,91010-0269[5]UCLA Medical Center Los Angeles,California,United States,90095[6]University of California,Davis - Health Systems Sacramento,California,United States,95817[7]UCSF Medical Center at Mission Bay San Francisco,California,United States,94158[8]Los Angeles Biomedical Research Institute at Harbor - UCLA Medical Torrance,California,United States,90502[9]Mayo Clinic in Florida Jacksonville,Florida,United States,32224[10]Emory University Atlanta,Georgia,United States,30322
研究目的：
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
